These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 9554878)

  • 1. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
    J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
    J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities.
    Kaltenbach RF; Nugiel DA; Lam PY; Klabe RM; Seitz SP
    J Med Chem; 1998 Dec; 41(25):5113-7. PubMed ID: 9836627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
    Debnath AK
    J Med Chem; 1999 Jan; 42(2):249-59. PubMed ID: 9925730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.
    Hultén J; Bonham NM; Nillroth U; Hansson T; Zuccarello G; Bouzide A; Aqvist J; Classon B; Danielson UH; Karlén A; Kvarnström I; Samuelsson B; Hallberg A
    J Med Chem; 1997 Mar; 40(6):885-97. PubMed ID: 9083477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V; Burello E; Miertus S
    Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
    Lam PY; Ru Y; Jadhav PK; Aldrich PE; DeLucca GV; Eyermann CJ; Chang CH; Emmett G; Holler ER; Daneker WF; Li L; Confalone PN; McHugh RJ; Han Q; Li R; Markwalder JA; Seitz SP; Sharpe TR; Bacheler LT; Rayner MM; Klabe RM; Shum L; Winslow DL; Kornhauser DM; Hodge CN
    J Med Chem; 1996 Aug; 39(18):3514-25. PubMed ID: 8784449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
    Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
    Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
    J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative structure-activity relationship studies on cyclic cyanoguanidines acting as HIV-1 protease inhibitors.
    Gupta SP; Babu MS
    Bioorg Med Chem; 1999 Nov; 7(11):2549-53. PubMed ID: 10632065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
    Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
    J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. X-ray structure and conformational dynamics of the HIV-1 protease in complex with the inhibitor SDZ283-910: agreement of time-resolved spectroscopy and molecular dynamics simulations.
    Ringhofer S; Kallen J; Dutzler R; Billich A; Visser AJ; Scholz D; Steinhauser O; Schreiber H; Auer M; Kungl AJ
    J Mol Biol; 1999 Mar; 286(4):1147-59. PubMed ID: 10047488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
    Wilkerson WW; Akamike E; Cheatham WW; Hollis AY; Collins RD; DeLucca I; Lam PY; Ru Y
    J Med Chem; 1996 Oct; 39(21):4299-312. PubMed ID: 8863807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes.
    Rezácová P; Pokorná J; Brynda J; Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezác J; Grantz Sasková K; Sieglová I; Plesek J; Sícha V; Grüner B; Oberwinkler H; Sedlácek' J; Kräusslich HG; Hobza P; Král V; Konvalinka J
    J Med Chem; 2009 Nov; 52(22):7132-41. PubMed ID: 19874035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series.
    Reich SH; Melnick M; Pino MJ; Fuhry MA; Trippe AJ; Appelt K; Davies JF; Wu BW; Musick L
    J Med Chem; 1996 Jul; 39(14):2781-94. PubMed ID: 8709109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
    Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
    J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping hydration water molecules in the HIV-1 protease/DMP323 complex in solution by NMR spectroscopy.
    Wang YX; Freedberg DI; Grzesiek S; Torchia DA; Wingfield PT; Kaufman JD; Stahl SJ; Chang CH; Hodge CN
    Biochemistry; 1996 Oct; 35(39):12694-704. PubMed ID: 8841113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.